e-Edition
Obituaries
In Loving Memory
Magazines
Subscribe
Login to Comment
Register
jobs
Menu
Home
News
Sports
Business
Entertainment
Classifieds
Life
Commentary
Contact
Recent Quotes
View Full List
My Watchlist
60 Degrees Pharmaceuticals, Inc. - Common Stock
AMERISAFE, Inc. - Common Stock
AltaGas Ltd Ord
Cinedigm Corp - Class A Common Stock
Iambic Therapeutics, Inc. - Common Stock
L'Air Liquide Sa ADR
Maple Gold Mines Ltd
Medalist Diversified, Inc. - Common Stock
Monster Beverage
Origin Agritech Limited - Ordinary Shares
Performance Food Group Company Common Stock
Portillo's Inc. - Class A Common Stock
Qualigen Therapeutics, Inc. - Common Stock
ReShape Lifesciences, Inc. - Common Stock
SI-BONE, Inc. - Common Stock
Skyharbour Res Ltd Ord
Skyworks Solutions, Inc. - Common Stock
Taiga Gold Corp
Taysha Gene Therapies, Inc. - Common Stock
Themes Cybersecurity ETF
Troilus Mng Corp
Valneva SE - American Depositary Shares
Waterside Cap Cp
Edit Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Panbela Therapeutics, Inc. - Common Stock
(OP:
PBLA
)
0.0010
UNCHANGED
Delayed Quote
Updated: 10:24 AM EDT, Oct 15, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Panbela Therapeutics, Inc. - Common Stock
Panbela to Host Third Quarter 2024 Earnings Conference Call on November 14, 2024
October 31, 2024
From
Panbela Therapeutics, Inc.
Via
GlobeNewswire
First Patient Enrolled in Phase I Program in STK11 Mutant Non-Small Cell Lung Cancer at Moffitt Cancer Center
September 24, 2024
From
Panbela Therapeutics, Inc.
Via
GlobeNewswire
Panbela to Host Second Quarter 2024 Earnings Conference Call on Aug 13, 2024
July 30, 2024
From
Panbela Therapeutics, Inc.
Via
GlobeNewswire
Panbela Therapeutics Announces Third Independent Safety Review of Phase 3 ASPIRE Clinical Trial DSMB Recommended Continuation with No Trial Modification
June 24, 2024
From
Panbela Therapeutics, Inc.
Via
GlobeNewswire
Panbela Announces Oral Presentation at Digestive Disease Week (DDW):
June 10, 2024
Evaluation of the Safety and Efficacy of Eflornithine (Difluoromethylornithine, DFMO) in Patients with Gastric Premalignant Conditions in the High Incidence Areas of Latin American
From
Panbela Therapeutics, Inc.
Via
GlobeNewswire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
wpDiscuz
Insert